
Endocrinologist

No OPD information available
Type 1 Diabetes (T1D)
Diabetic Ketoacidosis
Low Blood Sugar
Type 2 Diabetes (T2D)
Diabetic Nephropathy
Diabetic Neuropathy
Diabetic Retinopathy
Gangrene
Heart Attack
Kidney Transplant
Low Sodium Level
Obesity
Peripheral Neuropathy
Scrotal Swelling
Wilson Disease
Peter G. Colman is a male healthcare provider who helps people with different health issues like Type 1 Diabetes, Type 2 Diabetes, Diabetic Neuropathy, Heart Attack, and more. He uses special skills and treatments to care for his patients.
Peter G. Colman talks to his patients in a way that makes them feel comfortable and safe. Patients trust him because he listens to their concerns and explains things clearly.
Peter G. Colman stays up-to-date with the latest medical knowledge and research. This helps him provide the best care for his patients and offer them the most effective treatments available.
Peter G. Colman works well with other medical professionals. He shares knowledge and collaborates with colleagues to ensure his patients receive comprehensive care.
Peter G. Colman's work has had a positive impact on many patients' lives. His dedication and expertise have helped improve the health and well-being of those he treats.
One of Peter G. Colman's notable publications is about the link between SARS-CoV-2 infection and childhood islet autoimmunity. This shows his commitment to advancing medical knowledge and sharing important findings with the medical community.
Peter G. Colman is also involved in a clinical trial to evaluate the effectiveness and safety of a treatment for retinopathy in adults with Type 1 Diabetes. This shows his dedication to research and finding new ways to help patients.
In summary, Peter G. Colman is a caring and knowledgeable healthcare provider who works diligently to improve the health of his patients through his expertise, communication skills, commitment to staying updated with the latest medical knowledge, and involvement in research to find better treatments.
Enrollment Status: Recruiting
Published: April 04, 2025
Intervention Type: Drug
Study Drug: Fenofibrate
Study Phase: Phase 3
